Action myoclonus-renal failure syndrome
Overview
Action myoclonus-renal failure syndrome (AMRF) is a rare epilepsy syndrome characterized by progressive myoclonus epilepsy in association with primary glomerular disease. Patients present with neurologic symptoms (including tremor, action myoclonus, tonic-clonic seizures, later ataxia and dysarthria) that may precede, occur simultaneously or be followed by renal manifestations including proteinuria that progresses to nephrotic syndrome and end-stage renal disease. In some patients, sensorimotor peripheral neuropathy, sensorineural hearing loss and dilated cardiomyopathy are associated symptoms.
Symptoms
Neurological Symptoms
Action Myoclonus: Sudden, brief, involuntary muscle jerks in the face, torso, and limbs that worsen when attempting voluntary movement.
Tremors: Fine or rhythmic shaking in the hands, fingers, and sometimes the head or tongue.
Seizures: Generalized tonic-clonic or myoclonic seizures.Ataxia: Loss of balance and uncoordinated walking.
Peripheral Neuropathy: Weakness, numbness, or tingling in the limbs.Hearing Loss: Progressive sensorineural hearing loss.
Renal (Kidney) Symptoms
Proteinuria: Excess protein leaking into the urine, often an early sign.
Nephrotic Syndrome: Swelling (edema), low blood protein, and high cholesterol.
End-Stage Renal Disease (ESRD): Eventual severe loss of kidney function requiring dialysis or a transplant
Causes
SCARB2 Gene Mutation: Mutations (such as homozygous or compound heterozygous loss-of-function variants) in the SCARB2 gene directly cause the condition.
LIMP-2 Deficiency: The SCARB2 gene encodes the lysosomal integral membrane protein type 2 (LIMP-2).
Disrupted Lysosomal Function: LIMP-2 is essential for normal lysosomal trafficking and enzyme management (such as beta-glucocerebrosidase). Its deficiency leads to abnormal protein and lipid handling, cellular stress, and progressive damage primarily affecting neurons in the brain and glomeruli in the kidneys
Autosomal Recessive: A person must inherit two abnormal copies of the SCARB2 gene (one from each parent) to develop AMRF syndrome. Carriers of a single copy typically do not show symptoms
Diagnosis
Molecular Genetic Testing: Confirms the diagnosis by finding biallelic loss-of-function or homozygous mutations in the SCARB2 gene via NCBI Bookshelf.
Clinical Evaluation: Assesses early signs like hand tremors, action myoclonus, ataxia, and generalized seizures.
Renal Assessment: Tests for proteinuria, hypoalbuminemia, and declining glomerular filtration leading to end-stage renal disease.
Electrophysiological Testing: Uses electroencephalography (EEG) and electromyography (EMG) to check brain and muscle activity patterns.
Kidney Biopsy: May show focal segmental glomerulosclerosis or collapsing glomerulopathy.
Treatment
Anti-seizure and anti-myoclonic medications: Drugs like clonazepam, levetiracetam, valproic acid, and piracetam help control myoclonic jerks and seizures.
Therapies: Physical, occupational, and speech therapy assist in maintaining motor function and daily living activities.
Experimental approaches: Substrate reduction therapy (such as miglustat) has shown potential in halting neurological progression in specific genetic (SCARB2) cases.
Nephrology care: Regular monitoring of kidney function and blood pressure control using renin-angiotensin-aldosterone system (RAAS) inhibitors.
Renal replacement therapy: Progression to end-stage renal disease is managed effectively with dialysis or kidney transplantation. Transplantation normalizes kidney function, though neurological symptoms typically continue to progress
Type of Doctor Department : A neurologist and a nephrologist
.jpg)
Comments
Post a Comment